Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Implant artificiel PerQdisc inséré chirurgicalement lombaire après une nucléectomie 3 (LOPAIN3)

4 novembre 2026 mis à jour par: Spinal Stabilization Technologies

Premier plan d'investigation clinique dans un essai sur l'homme Implant artificiel PerQdisc à insertion chirurgicale lombaire après nucléectomie "LOPAIN3"

This study is a First in Human, prospective, multi-center clinical study intended to collect safety and performance information for the Spinal Stabilization Technologies PerQdisc® Nucleus Replacement System and procedure concurrently following a successful discectomy using a minimally invasive posterolateral (MIPL) approach. Patients that are at least 21 years or older, presenting with symptomatic radiculopathy from a focal lumbar disc herniation that requires surgical decompression will be included in this study.

Aperçu de l'étude

Statut

Suspendu

Les conditions

Intervention / Traitement

Description détaillée

The PerQdisc® Nucleus Replacement System is comprised of an in situ formed silicone-based prosthesis with its delivery system, implant fill device, dispenser gun, a disc access system and two different imaging balloons. For this trial, the PerQdisc® will be implanted using minimally invasive posterolateral (MIPL) approach. The implanted device provides an effective means of replacing dysfunctional nucleus pulposus while supporting the native annulus fibrosis to bridge annular defects.

Patients that suffer clinically significant lumbar disc herniations currently undergo discectomy procedures to relieve nerve root compression. The standard discectomy procedure does not correct the annular defect associated with the herniation and is associated with a risk for re-herniation. In addition, the progressive loss of disc height and overall lack of disc turgor and weight bearing capacity is thought to be associated with downstream degenerative changes that may lead to chronic low back pain and premature spondylosis.

Type d'étude

Interventionnel

Inscription (Estimé)

50

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • Ouzbékistan
    • Tashkent
      • Tashkent, Tashkent, Ouzbékistan, 100007
        • Republican Specialized Scientific Practical Medical Center of Endocrinology named after Academician Y.Kh. Turakulova
  • Paraguay
      • Asunción, Paraguay, 1101
        • Sanatorio Americano

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

21 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Patient is skeletally mature and at least 21 years of age.
  • Patient has a lumbar disc herniation, between L1-S1, with compressive radiculopathy of the traversing nerve root requiring partial discectomy or sequestrectomy. Only one lumbar disc may be treated with the PerQdisc device.
  • Patient must have an overall disc herniation (extrusion or protrusion) such that half or less of the width of the dorsal annulus of the spinal canal, is affected by the herniation. The width of the canal is defined by the lateral recesses and the central canal (i.e. pedicle to pedicle).
  • Patient must have a minimum of 6 mm of disc height as measured in the center of the affected disc.
  • Patient is willing and able to give informed consent.
  • All surgeries must be approved by at least 2 members of the Medical Advisory Board (MAB) - potential anatomical limitations of safely accessing Kambin's, extent of annular disruption, as well as overall patient criteria will be evaluated

Exclusion Criteria:

  • Patient has had prior lumbar spine surgery at the index level (nucleoplasy is acceptable).
  • Patient has had spinal fusion in the lumbar spine. Cervical or thoracic fusion is allowed as long as there are no neurologic deficits in the lower extremities.
  • Patient has spondyloarthropathy or other spondylolisthesis greater than 4 mm or spondylolysis at the index level (on standing X-ray).
  • Patient has underlying moderate or severe spinal stenosis (congenital, degenerative, or due to epidural lipomatosis) at any level. If the index level shows stenosis due to the disc herniation, it is acceptable if the index level is going to be treated concurrently with the PerQdsic procedure.
  • Patient has compressive radiculopathy of the exiting nerve root at the index level.
  • Patient has significant facet disease. Significant is defined as clinically confirmed by diagnostic block or radiologically grade 2 or higher (mild joint narrowing and irregularity are acceptable, but not sclerosis or osteophyte formation).
  • Patient has any known active malignancy.
  • Patient has previously undergone or currently on immunosuppressive therapy. Steroids used to treat inflammation are allowed.
  • Patient has active local or systemic infection.
  • Patient has been diagnosed with hepatitis, rheumatoid arthritis, lupus erythematosus, or other autoimmune disease including AIDS, AIDS related complex (ARC) and HIV.
  • Patient has diabetes mellitus (Type 1 or 2) requiring daily insulin management.
  • Patient has osteopenia of the spine (T-score of -1.0 or lower). All patients 50 years of age or older, and any post menopausal women with a history of fractures should have a dual x-ray absorptiometry (DEXA) scan to confirm exclusion.
  • Patient has morbid obesity defined as a body mass index (BMI) more than 35 (>35).
  • Patient has a known allergy to silicone or barium sulfate.
  • Patient has a broad disc herniation that is wider than ½ of the dorsal annulus forming the wall of the spinal canal
  • Patient requires decompression involving disruption of the midline bony-ligamentous elements (i.e. laminectomy).
  • Patient has a significant Schmorl's node at the level to be treated, or any Schmorl's nodes affecting 3 or more lumbar levels. Significant is defined as a large, rectangular or irregular shaped node that has an associated active inflammatory process (Modic I changes).
  • Patient has more than 20 degrees of mobility on flexion/extension radiographs at the index level
  • Patient has more than 10 degrees of lumbar scoliosis.
  • Patient belongs to a vulnerable population or has a condition such that his/her ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g. developmentally disabled, prisoner, chronic alcohol/ substance abuser)
  • Patient is pregnant or plans to become pregnant during the course of the study. Pregnancy ruled out by serum HCG. If patient becomes pregnant during the course of the study and wishes to continue study participation, a new Pregnancy Informed Consent must be completed.

Intraoperative Exclusion:

  • Poor radiological visualization of Kambin's triangle
  • Patient has annular defect following surgical treatment of the disc herniation/protrusion that is greater than 6 mm
  • Sustained irritation of the exiting nerve root during any aspect of the annular dilation technique (leg movement or if performing with electrical monitoring) in spite of repositioning instruments.
  • Protrusion of the 50A Imaging Balloon up to or beyond the outer margin of the vertebra during the imaging steps.
  • Patient has a violated endplate as determined by imaging balloons during fluoroscopy.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Lumbar Disc Nucleus Replacement following discectomy

All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
Dispositif: PerQdisc Nucleus Replacement System

Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Safety: Number of Patients with Serious Adverse Events related to the PerQdisc
Délai: 12 months

Freedom from device- and procedure-related serious adverse events definitely related to the PerQdisc Device or the PerQdisc Surgical Procedure
12 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Performance: ODI
Délai: 3 months

Change in Oswestry Disability Index (ODI) comparing baseline to follow up visits using a patient reported outcome tool
3 months
Performance: ODI
Délai: 6 months

Change in Oswestry Disability Index (ODI) comparing baseline to follow up visits using a patient reported outcome tool
6 months
Performance: ODI
Délai: 12 months

Change in Oswestry Disability Index (ODI) comparing baseline to follow up visits using a patient reported outcome tool
12 months
Performance: ODI
Délai: 24 months

Change in Oswestry Disability Index (ODI) comparing baseline to follow up visits using a patient reported outcome tool
24 months
Performance: VAS Back
Délai: 3 months

Change in back pain values as measured by the 100 millimeter Visual Analog Scale (VAS)
3 months
Performance: VAS Back
Délai: 6 months

Change in back pain values as measured by the 100 millimeter Visual Analog Scale (VAS)
6 months
Performance: VAS Back
Délai: 12 months

Change in back pain values as measured by the 100 millimeter Visual Analog Scale (VAS)
12 months
Performance: VAS Back
Délai: 24 months

Change in back pain values as measured by the 100 millimeter Visual Analog Scale (VAS)
24 months
Performance: VAS Leg
Délai: 3 months

Change in leg pain values as measured by the 100 millimeter Visual Analog Scale (VAS)
3 months
Performance: VAS Leg
Délai: 6 months

Change in leg pain values as measured by the 100 millimeter Visual Analog Scale (VAS)
6 months
Performance: VAS Leg
Délai: 12 months

Change in leg pain values as measured by the 100 millimeter Visual Analog Scale (VAS)
12 months
Performance: VAS Leg
Délai: 24 months

Change in leg pain values as measured by the 100 millimeter Visual Analog Scale (VAS)
24 months
Performance: Analgesic Score
Délai: 3 months

Change in level of pain medication used comparing baseline to follow up visits based on a medication scale from 0 (no meds) to 4 (high dose opioids)
3 months
Performance: Analgesic Score
Délai: 6 months

Change in level of pain medication used comparing baseline to follow up visits based on a medication scale from 0 (no meds) to 4 (high dose opioids)
6 months
Performance: Analgesic Score
Délai: 12 months

Change in level of pain medication used comparing baseline to follow up visits based on a medication scale from 0 (no meds) to 4 (high dose opioids)
12 months
Performance: Analgesic Score
Délai: 24 months

Change in level of pain medication used comparing baseline to follow up visits based on a medication scale from 0 (no meds) to 4 (high dose opioids)
24 months
Safety: Number of Patients with Reherniation/recurrent disc herniation
Délai: 3 months

Freedom from reherniation/recurrent disc herniation
3 months
Safety: Number of Patients with Reherniation/recurrent disc herniation
Délai: 6 months

Freedom from reherniation/recurrent disc herniation
6 months
Safety: Number of Patients with Reherniation/recurrent disc herniation
Délai: 12 months

Freedom from reherniation/recurrent disc herniation
12 months
Safety: Number of Patients with Reherniation/recurrent disc herniation
Délai: 24 months

Freedom from reherniation/recurrent disc herniation
24 months
Safety: Number of Patient that Received Supplemental fixation
Délai: 3 months

Freedom from supplemental fixation at the index level(s) including basivertebral nerve ablation, radiofrequency ablation or spinal cord stimulator
3 months
Safety: Number of Patient that Received Supplemental fixation
Délai: 6 months

Freedom from supplemental fixation at the index level(s) including basivertebral nerve ablation, radiofrequency ablation or spinal cord stimulator
6 months
Safety: Number of Patient that Received Supplemental fixation
Délai: 12 months

Freedom from supplemental fixation at the index level(s) including basivertebral nerve ablation, radiofrequency ablation or spinal cord stimulator
12 months
Safety: Number of Patient that Received Supplemental fixation
Délai: 24 months

Freedom from supplemental fixation at the index level(s) including basivertebral nerve ablation, radiofrequency ablation or spinal cord stimulator
24 months

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Exploratory Endpoint: Disch Height
Délai: 3 months

Disc height in millimeters at each clinical visit as measured on plain film X-ray
3 months
Exploratory Endpoint: Disch Height
Délai: 6 months

Disc height in millimeters at each clinical visit as measured on plain film X-ray
6 months
Exploratory Endpoint: Disch Height
Délai: 12 months

Disc height in millimeters at each clinical visit as measured on plain film X-ray
12 months
Exploratory Endpoint: Disch Height
Délai: 24 months

Disc height in millimeters at each clinical visit as measured on plain film X-ray
24 months
Exploratory Endpoint: RoM
Délai: 3 months

Preservation of range of movement (expressed in degrees) at the index and adjacent levels at baseline compared to follow-up using flexion/extension radiographs
3 months
Exploratory Endpoint: RoM
Délai: 6 months

Preservation of range of movement (expressed in degrees) at the index and adjacent levels at baseline compared to follow-up using flexion/extension radiographs
6 months
Exploratory Endpoint: RoM
Délai: 12 months

Preservation of range of movement (expressed in degrees) at the index and adjacent levels at baseline compared to follow-up using flexion/extension radiographs
12 months
Exploratory Endpoint: RoM
Délai: 24 months

Preservation of range of movement (expressed in degrees) at the index and adjacent levels at baseline compared to follow-up using flexion/extension radiographs
24 months
Exploratory Endpoint: Neurological Status
Délai: 3 months

Maintenance and/or improvement of baseline neurologic status through physical assessment evaluating nerve compression at baseline and post-surgical follow-up using pain, motor strength, and sensation feedback from the patient on a 0 (no compression) to 5 (major compression) scale
3 months
Exploratory Endpoint: Neurological Status
Délai: 6 months

Maintenance and/or improvement of baseline neurologic status through physical assessment evaluating nerve compression at baseline and post-surgical follow-up using pain, motor strength, and sensation feedback from the patient on a 0 (no compression) to 5 (major compression) scale
6 months
Exploratory Endpoint: Neurological Status
Délai: 12 months

Maintenance and/or improvement of baseline neurologic status through physical assessment evaluating nerve compression at baseline and post-surgical follow-up using pain, motor strength, and sensation feedback from the patient on a 0 (no compression) to 5 (major compression) scale
12 months
Exploratory Endpoint: Neurological Status
Délai: 24 months

Maintenance and/or improvement of baseline neurologic status through physical assessment evaluating nerve compression at baseline and post-surgical follow-up using pain, motor strength, and sensation feedback from the patient on a 0 (no compression) to 5 (major compression) scale
24 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Spinal Stabilization Technologies

Collaborateurs

Raylytic GmbH

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

16 juin 2023

Achèvement primaire (Estimé)

16 septembre 2027

Achèvement de l'étude (Estimé)

16 juin 2028

Dates d'inscription aux études

Première soumission

30 janvier 2023

Première soumission répondant aux critères de contrôle qualité

7 février 2023

Première publication (Réel)

17 février 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

9 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • DPQ114.B: LOPAIN3

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner